Skip to main content

Table 2 Baseline demographic and clinical variables and baseline domain scores associated with overall survival

From: Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Variable

Univariatea

Multivariatea

HR (95 % CI)

P

HR (95 % CI)

P

Baseline characteristics

Age <70 y (vs. ≥70 y)

0.603 (0.349–1.258)

0.208

  

Sex, male (vs. female)

0.544 (0.254–1.167)

0.118

  

HCV infection (vs. other etiology)

1.138 (0.610–0.122)

0.684

  

Child Pugh = 5 (vs. ≥6)

0.419 (0.227–0.812)

0.009

  

TMN stage III (vs. IV)

0.695 (0.371–1.304)

0.257

  

Vascular invasion - (vs. +)

0.475 (0.204–0.945)

0.034

  

Tumor size <50 mm (vs. ≥50 mm)

0.831 (0.441–1.567)

0.567

  

Previous curative therapy: Yes (vs. No)

0.255 (0.129–0.504)

<0.001

0.235 (0.116–0.477)

<0.001

AFP <100 (vs. ≥100)

0.893 (0.473–1.686)

0.726

  

DCP <1000 (vs. ≥1000)

0.548 (0.280–1.070)

0.078

  

Initial dose of sorafenib 800 mg (vs. <800 mg)

1.137 (0.611–2.115)

0.686

  

Treatment duration ≥5 months (vs. <5)

0.608 (0.325–1.138)

0.120

  

HRQOL domain scores ≥40b:

Physical functioning

0.529 (0.278–1.008)

0.053

0.479 (0.245–0.935)

0.031

Role physical

0.595 (0.314–1.127)

0.111

  

Bodily pain

1.686 (0.772–3.676)

0.190

  

General health

1.331 (0.644–2.755)

0.440

  

Vitality

0.842 (0.383–1.848)

0.669

  

Social functioning

0.833 (0.411–1.684)

0.610

  

Role emotional

0.957 (0.473–1.938)

0.904

  

Mental health

2.053 (0.893–4.717)

0.090

  
  1. HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin, HRQOL health related quality of life
  2. aCox proportional hazards regression analysis
  3. bAll domain scores are relative to scores <40
  4. All variables with P values <0.06 in the univariate analysis were included in the multivariate analysis